SUTRO BIOPHARMA, INC. (STRO) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinSTRO / S&P 33.28% / 15.20% |
LoseSTRO / S&P -56.25% / 15.00% |
LoseSTRO / S&P -30.33% / 50.40% |
| 2026-Q12/3 |
WinSTRO / S&P 115.30% / -4.33% |
WinSTRO / S&P 49.94% / 11.30% |
LoseSTRO / S&P -31.52% / 27.70% |
| 2025-Q42/3 |
WinSTRO / S&P 32.99% / 2.65% |
WinSTRO / S&P 65.18% / 9.00% |
LoseSTRO / S&P 9.55% / 13.40% |
| 2025-Q32/3 |
WinSTRO / S&P 22.54% / 8.12% |
LoseSTRO / S&P -34.36% / 4.61% |
WinSTRO / S&P 2974.40% / 13.45% |
| 2025-Q21/3 |
LoseSTRO / S&P 9.23% / 10.94% |
LoseSTRO / S&P -38.31% / 4.83% |
WinSTRO / S&P 2508.84% / 10.63% |
| 2025-Q11/3 |
LoseSTRO / S&P -64.67% / -4.27% |
LoseSTRO / S&P -56.88% / 4.98% |
WinSTRO / S&P 2373.03% / 10.57% |
| 2024-Q41/3 |
LoseSTRO / S&P -46.82% / 2.41% |
LoseSTRO / S&P -59.64% / 5.25% |
WinSTRO / S&P 1534.83% / 6.15% |
| 2024-Q32/3 |
WinSTRO / S&P 18.09% / 5.89% |
WinSTRO / S&P 230.90% / 5.89% |
LoseSTRO / S&P -57.04% / 6.11% |
| 2024-Q21/3 |
LoseSTRO / S&P -48.14% / 4.28% |
WinSTRO / S&P 197.83% / 5.38% |
LoseSTRO / S&P -40.49% / 5.12% |
| 2024-Q12/3 |
WinSTRO / S&P 31.70% / 10.56% |
WinSTRO / S&P 106.66% / 5.71% |
LoseSTRO / S&P -36.13% / 5.59% |
| 2023-Q42/3 |
WinSTRO / S&P 23.63% / 11.69% |
WinSTRO / S&P 126.84% / 6.81% |
LoseSTRO / S&P -24.89% / 7.78% |
| 2023-Q31/3 |
LoseSTRO / S&P -25.38% / -3.27% |
LoseSTRO / S&P -30.31% / 7.52% |
WinSTRO / S&P 12.36% / -5.03% |
| 2023-Q20/3 |
LoseSTRO / S&P 0.65% / 8.74% |
LoseSTRO / S&P 6.96% / 9.50% |
LoseSTRO / S&P -14.53% / -8.57% |
| 2023-Q12/3 |
LoseSTRO / S&P -42.82% / 7.50% |
WinSTRO / S&P 40.35% / 10.77% |
WinSTRO / S&P -3.64% / -15.69% |
| 2022-Q41/3 |
WinSTRO / S&P 45.59% / 7.56% |
LoseSTRO / S&P 9.52% / 11.88% |
LoseSTRO / S&P STRO unavailable / -17.99% |
| 2022-Q32/3 |
WinSTRO / S&P 6.53% / -4.88% |
WinSTRO / S&P 17.29% / 13.47% |
LoseSTRO / S&P STRO unavailable / -1.41% |
| 2022-Q20/3 |
LoseSTRO / S&P -36.62% / -16.10% |
LoseSTRO / S&P -22.74% / 13.71% |
LoseSTRO / S&P STRO unavailable / 11.04% |
| 2022-Q10/3 |
LoseSTRO / S&P -44.76% / -4.60% |
LoseSTRO / S&P 5.75% / 15.97% |
LoseSTRO / S&P STRO unavailable / 42.23% |
| 2021-Q41/3 |
LoseSTRO / S&P -21.23% / 11.03% |
WinSTRO / S&P 44.84% / 15.00% |
LoseSTRO / S&P STRO unavailable / 96.40% |
| 2021-Q32/3 |
WinSTRO / S&P 1.61% / 0.58% |
WinSTRO / S&P 30.07% / 10.77% |
LoseSTRO / S&P STRO unavailable / 69.42% |
| 2021-Q21/3 |
LoseSTRO / S&P -18.32% / 8.55% |
WinSTRO / S&P 71.16% / 6.58% |
LoseSTRO / S&P STRO unavailable / 51.81% |
| 2021-Q11/3 |
LoseSTRO / S&P 4.84% / 6.17% |
WinSTRO / S&P 21.74% / -1.06% |
LoseSTRO / S&P STRO unavailable / 7.39% |
| 2020-Q42/3 |
WinSTRO / S&P 116.02% / 12.15% |
WinSTRO / S&P -0.03% / -3.72% |
LoseSTRO / S&P STRO unavailable / -33.42% |
| 2020-Q31/3 |
WinSTRO / S&P 29.51% / 8.93% |
LoseSTRO / S&P -9.44% / -2.04% |
LoseSTRO / S&P STRO unavailable / -27.10% |
| 2020-Q20/3 |
LoseSTRO / S&P -23.92% / 20.54% |
LoseSTRO / S&P -12.75% / -0.46% |
LoseSTRO / S&P STRO unavailable / -27.11% |
| 2020-Q11/3 |
WinSTRO / S&P -7.27% / -19.60% |
LoseSTRO / S&P 0.01% / 3.47% |
LoseSTRO / S&P STRO unavailable / -14.75% |
| 2019-Q42/3 |
WinSTRO / S&P 21.01% / 9.07% |
WinSTRO / S&P 11.24% / 5.36% |
LoseSTRO / S&P STRO unavailable / 2.99% |
| 2019-Q31/3 |
LoseSTRO / S&P -20.12% / 1.70% |
WinSTRO / S&P 116.13% / 5.02% |
LoseSTRO / S&P STRO unavailable / 0.21% |
| 2019-Q21/3 |
LoseSTRO / S&P -0.09% / 4.30% |
WinSTRO / S&P 39.47% / 6.64% |
LoseSTRO / S&P STRO unavailable / 8.65% |
| 2019-Q11/3 |
WinSTRO / S&P 26.27% / 13.65% |
LoseSTRO / S&P STRO unavailable / 8.12% |
LoseSTRO / S&P STRO unavailable / 14.29% |
| 2018-Q40/3 |
LoseSTRO / S&P -39.87% / -13.52% |
LoseSTRO / S&P STRO unavailable / 9.05% |
LoseSTRO / S&P STRO unavailable / 18.23% |
| 2018-Q30/3 |
LoseSTRO / S&P STRO unavailable / 7.71% |
LoseSTRO / S&P STRO unavailable / 10.21% |
LoseSTRO / S&P STRO unavailable / 19.06% |
| 2018-Q20/3 |
LoseSTRO / S&P STRO unavailable / 3.43% |
LoseSTRO / S&P STRO unavailable / 9.03% |
LoseSTRO / S&P STRO unavailable / 14.46% |
| 2018-Q10/3 |
LoseSTRO / S&P STRO unavailable / -0.76% |
LoseSTRO / S&P STRO unavailable / 7.68% |
LoseSTRO / S&P STRO unavailable / 12.46% |
| 2017-Q40/3 |
LoseSTRO / S&P STRO unavailable / 6.64% |
LoseSTRO / S&P STRO unavailable / 7.03% |
LoseSTRO / S&P STRO unavailable / 13.82% |
| 2017-Q30/3 |
LoseSTRO / S&P STRO unavailable / 4.48% |
LoseSTRO / S&P STRO unavailable / 5.68% |
LoseSTRO / S&P STRO unavailable / 17.57% |
| 2017-Q20/3 |
LoseSTRO / S&P STRO unavailable / 3.09% |
LoseSTRO / S&P STRO unavailable / 4.83% |
LoseSTRO / S&P STRO unavailable / 17.74% |
| 2017-Q10/3 |
LoseSTRO / S&P STRO unavailable / 6.07% |
LoseSTRO / S&P STRO unavailable / 3.67% |
LoseSTRO / S&P STRO unavailable / 13.32% |
| 2016-Q40/3 |
LoseSTRO / S&P STRO unavailable / 3.82% |
LoseSTRO / S&P STRO unavailable / 2.09% |
LoseSTRO / S&P STRO unavailable / 7.05% |
| 2016-Q30/3 |
LoseSTRO / S&P STRO unavailable / 3.85% |
LoseSTRO / S&P STRO unavailable / 0.20% |
LoseSTRO / S&P STRO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | STRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 147.79% | 20.78% |
| Annualized return | 147.79% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | STRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -90.48% | 83.14% |
| Annualized return | -37.52% | 12.86% |
10Y · 2018-09-27 to 2026-08-27
| Metric | STRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -85.98% | 319.30% |
| Annualized return | -17.84% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |